Reported 24 days ago
Pfizer's impressive 5.7% dividend yield stands out in the pharmaceutical sector, but its staggering payout ratio of 436% raises red flags over sustainability. Despite facing a significant decline in stock value due to a slump in COVID-19 vaccine sales, Pfizer retains a strong market presence and management's commitment to maintaining its dividend remains firm. Analysts express cautious optimism, emphasizing the importance of monitoring financial health and potential improvements from new drug launches. Investors must weigh the high yield against risks before making decisions.
Source: YAHOO